Jason I Herschkowitz
Overview
Explore the profile of Jason I Herschkowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
5214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hang B, Jassem E, Mohammed H, Wan L, Herschkowitz J, Fan J
APL Bioeng
. 2022 Dec;
6(4):046107.
PMID: 36505506
Endothelial cells (ECs) possess a strong intrinsic clockwise (CW, or rightward) chirality under normal conditions. Enervating this chirality of ECs significantly impairs the function of the endothelial barrier. Malignant tumor...
2.
Bai F, Wang C, Liu X, Hollern D, Liu S, Fan C, et al.
Cell Death Dis
. 2022 Mar;
13(3):195.
PMID: 35236825
BRCA1 deficient breast cancers are aggressive and chemoresistant due, in part, to their enrichment of cancer stem cells that can be generated from carcinoma cells by an epithelial-mesenchymal transition (EMT)....
3.
Ropri A, DeVaux R, Eng J, Chittur S, Herschkowitz J
Breast Cancer Res
. 2021 Oct;
23(1):101.
PMID: 34717732
Background: Increased breast cancer screening over the past four decades has led to a substantial rise in the diagnosis of ductal carcinoma in situ (DCIS). Although DCIS lesions precede invasive...
4.
Kurzatkowska K, Pazos 2nd M, Herschkowitz J, Hepel M
Int J Mol Sci
. 2021 Feb;
22(3).
PMID: 33572999
The interactions of chemotherapeutic drugs with nanocage protein apoferritin (APO) are the key features in the effective encapsulation and release of highly toxic drugs in APO-based controlled drug delivery systems....
5.
Kulwatno J, Gong X, DeVaux R, Herschkowitz J, Mills K
Tissue Eng Part A
. 2021 Jan;
27(7-8):454-466.
PMID: 33397202
Ductal carcinoma (DCIS) is a precancerous stage breast cancer, where abnormal cells are contained within the duct, but have not invaded into the surrounding tissue. However, only 30-40% of DCIS...
6.
Nguyen T, Alchalabi S, Oluwatoyosi A, Ropri A, Herschkowitz J, Rosen J
RNA Biol
. 2020 Jun;
17(11):1535-1549.
PMID: 32522127
The purpose of this review is to highlight several areas of lncRNA biology and cancer that we hope will provide some new insights for future research. These include the relationship...
7.
DeVaux R, Ropri A, Grimm S, Hall P, Herrera E, Chittur S, et al.
J Cell Biochem
. 2020 Jan;
121(7):3465-3478.
PMID: 31907974
Ductal carcinoma in situ (DCIS) is a nonobligate precursor to invasive breast cancer. Only a small percentage of DCIS cases are predicted to progress; however, there is no method to...
8.
Herschkowitz J, Behbod F
J Mammary Gland Biol Neoplasia
. 2018 Nov;
23(4):189-190.
PMID: 30406903
No abstract available.
9.
DeVaux R, Herschkowitz J
J Mammary Gland Biol Neoplasia
. 2018 Oct;
23(4):223-235.
PMID: 30306389
Ductal Carcinoma in Situ (DCIS) is an early breast cancer lesion that is considered a nonobligate precursor to development of invasive ductal carcinoma (IDC). Although only a small subset of...
10.
Santiago T, DeVaux R, Kurzatkowska K, Espinal R, Herschkowitz J, Hepel M
Int J Nanomedicine
. 2017 Nov;
12:7763-7776.
PMID: 29123391
Advanced and metastatic cancer forms are extremely difficult to treat and require high doses of chemotherapeutics, inadvertently affecting also healthy cells. As a result, the observed survival rates are very...